|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Non-hepatitis | Hepatitis (all grade) | Hepatitis (G3/4) | P-value | P-value |
| Total number (%) | 185 (91.6%) | 17(8.4%) | 8 (4.0%) | Non vs all | Non vs G3/4 |
| ΔWBC 0–4w†  Supplementary Table 1. Changes in blood count and incidence of irAE hepatitis  ΔWBC 0–8w†  ΔNeut 0–4w†  ΔNeut 0–8w†  ΔLymph 0–4w†  ΔLymph 0–8w†  ΔNLR 0–4w†  ΔNLR 0–8w†  ΔEosino 0–4w†  ΔEosino 0–8w† | 500 (–12900–12300)  500 (–16400–16500)  374 (–11619–12048)  257 (–12529–28921)  1235 (–1337–15931)  132 (1206–22059)  –0.083 (–11.54–11.73)  0.041 (–13.06–40.91)  34.9 (–798–3810)  31 (–877–5139) | 1200 (–1000–7800)  300 (–1700–4100)  871 (–2910–4203)  –82 (–2027–4137)  350 (–624–2750)  –10 (–700–1822)  0.063 (–6.84–3.49)  –0.28 (–4.7–8.08)  21 (–122–196)  10 (–192–426) | 1450 (–1000–7800)  1100 (–1700–4100)  1196 (–2910–4203)  981 (–2027–4137)  189 (–317–2750)  –132 (–575–873)  0.14 (–6.84–2.45)  1.68 (–4.28–3.23)  15 (–122–196)  10 (–138–426) | n.s.  n.s.  n.s.  n.s.  n.s.  n.s.  n.s.  n.s.  n.s.  n.s. | n.s.  n.s.  n.s.  n.s.  n.s.  n.s.  n.s.  n.s.  n.s.  n.s. |

irAE: immune checkpoint inhibitor related adverse events, WBC: white blood cell, Neut: neutrophil count, Lymph: lymphocyte count,

NLR; Neutrophil/Lymphocyte Ratio, Eosino; eosinophil count, †Data are shown as median (range) values.

Supplementary Table 2. The relationship between irAE hepatitis and other irAEs

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | irAEs other than hepatitis | | | | | |
|  | n | Total | Colitis | Pneumonitis | Nephritis | Endocrinopathies | Other |
| irAE hepatitis | 17 | 4 | 1 | 2 | 0 | 0 | 1 |
| Non–irAE hepatitis | 185 | 62 | 7 | 14 | 3 | 24 | 14 |

irAEs: immune checkpoint inhibitor related adverse events

Table 4. Principal characteristics of eight patients with grade ≥3 irAE hepatitis